Search | Clinical Trials Finder

Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Conditions: Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit/Hyperactivity Disorder (ADHD), Intermittent Explosive Disorder, Impulse-Control Disorders, Adjustment Disorder, Bipolar Disorder, Pervasive Developmental Disorder
Interventions: Risperdal; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 4 Years to 14 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
Interventions: Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active); Device
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 55 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Sleep, Physical Activity
Interventions: Go/No-Go Task, Delay discounting task, Mirror Tracing Persistence Task, Spatial Span, Stop Signal Task, Flanker task; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 8 Years to 12 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Healthy, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate, Naltrexone, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 35 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Stroke
Interventions: Less-Impaired Arm Training, Contralesional Arm Comparison; Behavioral
Lead sponsor: Robert L. Sainburg; Other
Eligibility: 18 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Los Angeles, California • Hershey, Pennsylvania

Conditions: Spatial Neglect, Deficits in Attention Motor Control and Perception
Interventions: Prism Adaptation Treatment; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Traumatic Brain Injury, Veterans
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Attention Deficit Hyperactivity Disorder Combined
Interventions: Methylphenidate, Placebo; Drug
Lead sponsor: Donald Gilbert, MD, MS, FAAN, FAAP; Other
Eligibility: 8 Years to 12 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Alcohol-related Disorders, Drinking and Driving, Neurological Impairment
Interventions: Click City®: Alcohol; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 12 Years to 16 Years
Enrollment: 2,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Tourette Syndrome, Chronic Tic Disorder, Oppositional Defiant Disorder, ADHD
Interventions: Anger control training; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 11 Years to 16 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions: Use of Rare Beauty makeup products; Other
Lead sponsor: Casa Colina Hospital and Centers for Healthcare; Other
Eligibility: 18 Years to 55 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Pomona, California

Conditions: Adult Spinal Deformity
Interventions: Interventions; Procedure
Lead sponsor: AO Foundation, AO Spine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GM604, Placebo comparator; Drug
Lead sponsor: Genervon Biopharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Training Executive, Attention and Motor Skills (TEAMS), Parent support and education; Behavioral
Lead sponsor: Queens College, The City University of New York; Other
Eligibility: 48 Months to 71 Months
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Flushing, New York

Conditions: Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive, Intracerebral Hemorrhage Intraparenchymal
Interventions: Fingolimod, Placebo, Open-label Fingolimod; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: ADHD
Interventions: Dance Exergaming, Stationary Cycling, Music Listening; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Spatial Neglect, Stroke
Interventions: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim), Prism adaptation therapy (PAT) + Sham Stimulator, Gait Training; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Niemann-Pick Disease, Type C
Interventions: Parts A/B: Adrabetadex, Parts A/B: Sham Control; Drug · Other
Lead sponsor: Mandos LLC; Industry
Eligibility: 4 Years to 21 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 11 more

Conditions: Critical Illness, Neurologic Disorder
Interventions: "What Is Important to Us" Communication Intervention; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Months and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neurofibromatosis 1
Interventions: N-Acetyl cysteine, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 16 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Ischemic Stroke
Interventions: Non-invasive ventilatory treatment with auto-BPAP; Device
Lead sponsor: Technische Universität Dresden; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Esophageal Motility Disorders, Gastric Motor Dysfunction, Aspiration Pneumonia, Gastro Esophageal Reflux
Interventions: Prucalopride, Famotidine; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling; Drug · Behavioral
Lead sponsor: Joseph Blader; NIH
Eligibility: 6 Years to 12 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas

Search by objective public record fields.

The Myelin Disorders Biorepository Project

Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

Examination of the Dynamic Relationships of Sleep, Physical Activity, and Circadian Rhythmicity With Neurobehavioral Heterogeneity in ADHD

Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))

Predicting Ipsilesional Motor Deficits in Stroke With Dynamic Dominance Model

Prism Adaptation Therapy for Spatial Neglect

Awareness of Deficit After Combat-related Brain Injury

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

Evaluation of an School-based Alcohol Prevention Program for Middle School Students

Anger Control Training for Youth With Tourette Syndrome

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

Neurologic Complications in Spinal Deformity Surgery - Extension

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

Non-pharmacological Interventions for Preschoolers With Attention Deficit Hyperactivity Disorder (ADHD)

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

Effects of Performing Arts on Attention-deficit/Hyperactivity Disorder (ADHD)

Spatial-Motor Stroke-Rehab Study

VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

The "What Is Important to Us" Communication Intervention Pilot Clinical Trial

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

Reversal of the Neurological Deficit in Acute Stroke With the Signal of Efficacy Trial of Auto BPAP to Limit Damage From Suspected Sleep Apnea

Gastrointestinal Dysmotility on Aspiration Risk

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)